Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2001

View Archived Issues

Microcide reports results for Q2 2001

SkyePharma acquires interest in RTP Pharma

Allergan expands dermatology collaboration with Cytochroma

Novartis files Estradot in the European Union

Cell Genesys expands oncology pipeline with acquisition of Calydon

First kidney transplant patient enrolled in phase II trials of ISAtx-247

Noven signs product development agreement with Novartis for combination HRT patches

Genzyme receives marketing authorization for Fabrazyme

Questcor sells shares of common stock to Sigma-Tau

Novasite Pharmaceuticals and Aventis enter evaluation agreement

Endorex acquires CTD and adds two clinical-stage products to its pipeline

FDA grants fast track status to TransMID-107R for the treatment of brain cancer

Rigel and Novartis begin collaboration to discover antiangiogenic agents

Novel acylquinoline derivative developed for antiulcer applications

Mitsui Chemicals reports anilide derivatives useful as antiarrhythmic agents

Arizona State University scientists design new DNA reductive alkylating agents

Selective PDE5 inhibitors reported by scientists at Nippon Soda

Taisho patents compounds for treating bone or neurological diseases

Researchers at Sankyo identify new MMP inhibitors

Simultaneous filing of a Common Technical Document for Amevive in the U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...